

June 8, 2016
SymBio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

Notice concerning the Change of Major Shareholder

SymBio Pharmaceuticals Limited (Headquarters: Tokyo, “the Company”) announced today that the Company’s major shareholder has changed as follows.

1. Date of this change
May 31, 2016

2. Background to this change
The major shareholder of the Company has changed as set out in the large shareholding report submitted by Whiz Partners Inc. as of June 7, 2016.

3. Overview of the Company’s current major and largest shareholder
 - (1) Name: Whiz Healthcare Japan 2.0 Investment Limited Partnership
 - (2) Address: Atago Green Hills Mori Tower 36F, 2-5-1, Atago, Minato-ku, Tokyo
 - (3) Business: Investment Management Business

4. Voting rights and ownership percentage in respect of the Company before and after said change of the major and largest shareholder

	Number of voting rights (number of shares owned)	Ownership percentage in proportion to the total number of voting rights	Order of large shareholders
Before said change (as of May 20, 2016)	40,964 units (4,096,401 shares)	10.58%	The largest
After said change	31,939 units (3,193,901 shares)	8.25%	The largest

(Notes)

1. The number of shares excluded from the number of the Company’s outstanding shares due to the non-existence of voting rights: 75 shares
2. The number of the Company’s outstanding shares as of May 31, 2016: 38,710,924 shares.

(The number of the Company's outstanding shares as of May 20, 2016:
38,710,924 shares.)

3. The ownership percentage in proportion to the total number of voting rights is rounded off to the second decimal place.

5. Future outlook

The change of the major and largest shareholder of the Company will not impact the Company's performance or business relationship with other companies.

[Contact]

Investor Relations

Tel: +81(0)3 5472 1125